

Alessio Nencioni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/32974/publications.pdf>

Version: 2024-02-01

156
papers

6,205
citations

50276

46
h-index

85541

71
g-index

158
all docs

158
docs citations

158
times ranked

9424
citing authors

#	ARTICLE	IF	CITATIONS
1	Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment. <i>Haematologica</i> , 2022, 107, 1410-1426.	3.5	6
2	Neuropsychiatric Disorders and Frailty in Older Adults over the Spectrum of Cancer: A Narrative Review. <i>Cancers</i> , 2022, 14, 258.	3.7	2
3	Gut microbiota severely hampers the efficacy of NAD-lowering therapy in leukemia. <i>Cell Death and Disease</i> , 2022, 13, 320.	6.3	5
4	The use of immunotherapy in older patients with advanced non-small cell lung cancer. <i>Cancer Treatment Reviews</i> , 2022, 106, 102394.	7.7	16
5	Efficacy of High-Resolution Preoperative 3D Reconstructions for Lesion Localization in Oncological Colorectal Surgery—First Pilot Study. <i>Healthcare (Switzerland)</i> , 2022, 10, 900.	2.0	4
6	Effect of Geriatric Comanagement in Older Patients Undergoing Surgery for Gastrointestinal Cancer: A Retrospective, Before-and-After Study. <i>Journal of the American Medical Directors Association</i> , 2022, 23, 1868.e9-1868.e16.	2.5	7
7	Identification of new FK866 analogues with potent anticancer activity against pancreatic cancer. <i>European Journal of Medicinal Chemistry</i> , 2022, 239, 114504.	5.5	5
8	Exploring Cost-Effectiveness of the Comprehensive Geriatric Assessment in Geriatric Oncology: A Narrative Review. <i>Cancers</i> , 2022, 14, 3235.	3.7	6
9	Structure-Based Identification and Biological Characterization of New NAPRT Inhibitors. <i>Pharmaceuticals</i> , 2022, 15, 855.	3.8	8
10	Identification of NAPRT Inhibitors with Anti-Cancer Properties by In Silico Drug Discovery. <i>Pharmaceuticals</i> , 2022, 15, 848.	3.8	10
11	Comprehensive geriatric assessment in older adults with cancer: Recommendations by the Italian Society of Geriatrics and Gerontology (SIGG). <i>European Journal of Clinical Investigation</i> , 2021, 51, e13347.	3.4	9
12	Frailty assessment, hip fracture and long-term clinical outcomes in older adults. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13445.	3.4	19
13	SIRT6 enhances oxidative phosphorylation in breast cancer and promotes mammary tumorigenesis in mice. <i>Cancer & Metabolism</i> , 2021, 9, 6.	5.0	25
14	Social vulnerability is associated with increased mortality in older patients with cancer. <i>Journal of Geriatric Oncology</i> , 2021, 12, 470-472.	1.0	2
15	Osteosarcopenia in Very Old Age Adults After Hip Fracture: A Real-World Therapeutic Standpoint. <i>Frontiers in Medicine</i> , 2021, 8, 612506.	2.6	4
16	Advances in NAD-Lowering Agents for Cancer Treatment. <i>Nutrients</i> , 2021, 13, 1665.	4.1	38
17	Vitamin D and Folate as Predictors of MMSE in Alzheimer's Disease: A Machine Learning Analysis. <i>Diagnostics</i> , 2021, 11, 940.	2.6	15
18	Cross-Cultural Adaptation and Validation of the Italian Version of the Observational Scale of Level of Arousal. <i>Journal of the American Medical Directors Association</i> , 2021, 22, 1615-1620.e4.	2.5	1

#	ARTICLE	IF	CITATIONS
19	Safety and Feasibility of Fasting-Mimicking Diet and Effects on Nutritional Status and Circulating Metabolic and Inflammatory Factors in Cancer Patients Undergoing Active Treatment. <i>Cancers</i> , 2021, 13, 4013.	3.7	31
20	Increasing Anticholinergic Burden Is Associated With Social Vulnerability in the Oldest Old. <i>Journal of the American Medical Directors Association</i> , 2021, , .	2.5	0
21	Patterns of Comorbidity and In-Hospital Mortality in Older Patients With COVID-19 Infection. <i>Frontiers in Medicine</i> , 2021, 8, 726837.	2.6	17
22	Enhancing endocrine therapy activity via fasting cycles: biological rationale and clinical feasibility. <i>Molecular and Cellular Oncology</i> , 2021, 8, 1853492.	0.7	0
23	Differential modulation of SIRT6 deacetylase and deacylase activities by lysine-based small molecules. <i>Molecular Diversity</i> , 2020, 24, 655-671.	3.9	8
24	Development of a predictor of one-year mortality in older patients with cancer by geriatric and oncologic parameters. <i>Journal of Geriatric Oncology</i> , 2020, 11, 610-616.	1.0	4
25	Fasting-mimicking diet and hormone therapy induce breast cancer regression. <i>Nature</i> , 2020, 583, 620-624.	27.8	198
26	Clinical characteristics, management and in-hospital mortality of patients with coronavirus disease 2019 in Genoa, Italy. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1537-1544.	6.0	84
27	Amino acid depletion triggered by Ò-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death. <i>Blood Advances</i> , 2020, 4, 4312-4326.	5.2	19
28	Sirt6 inhibition delays the onset of experimental autoimmune encephalomyelitis by reducing dendritic cell migration. <i>Journal of Neuroinflammation</i> , 2020, 17, 228.	7.2	27
29	Synergistic effect of fasting-mimicking diet and vitamin C against KRAS mutated cancers. <i>Nature Communications</i> , 2020, 11, 2332.	12.8	90
30	A two-step surgery and a multidisciplinary approach in a centenarian patient with an acute presentation of right colon cancer. <i>BMC Surgery</i> , 2020, 20, 52.	1.3	3
31	The new small tyrosine kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs. <i>Haematologica</i> , 2020, 105, 2420-2431.	3.5	12
32	Social vulnerability underlying disability amongst older adults: A systematic review. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13239.	3.4	13
33	Nutrients in the Prevention of Alzheimer's Disease. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-20.	4.0	66
34	Reply to "Fasting in oncology: a word of caution". <i>Nature Reviews Cancer</i> , 2019, 19, 178-178.	28.4	4
35	Frailty assessment in elective gastrointestinal oncogeriatric surgery: Predictors of one-year mortality and functional status. <i>Journal of Geriatric Oncology</i> , 2019, 10, 716-723.	1.0	41
36	SIRT6 deacetylase activity regulates NAMPT activity and NAD(P)(H) pools in cancer cells. <i>FASEB Journal</i> , 2019, 33, 3704-3717.	0.5	48

#	ARTICLE	IF	CITATIONS
37	Reactive oxygen/nitrogen species contribute substantially to the antileukemia effect of APO866, a NAD lowering agent. <i>Oncotarget</i> , 2019, 10, 6723-6738.	1.8	19
38	Delirium, Frailty, and Fast-Track Surgery in Oncogeriatrics: Is There a Link?. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2018, 8, 33-41.	1.3	14
39	Induction of cell killing and autophagy by amphiphilic pyrrolidine derivatives on human pancreatic cancer cells. <i>European Journal of Medicinal Chemistry</i> , 2018, 150, 457-478.	5.5	6
40	Use of oral anticoagulant drugs in older patients with atrial fibrillation in internal medicine wards. <i>European Journal of Internal Medicine</i> , 2018, 52, e12-e14.	2.2	8
41	Cancer cell metabolic plasticity allows resistance to NAMPT inhibition but invariably induces dependence on LDHA. <i>Cancer & Metabolism</i> , 2018, 6, 1.	5.0	29
42	Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells' vulnerability to DNA-damaging agents. <i>Haematologica</i> , 2018, 103, 80-90.	3.5	48
43	The In-Hospital Length of Stay after Hip Fracture in Octogenarians: Do Delirium and Dementia Shape a New Care Process?. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 281-288.	2.6	6
44	Fasting and cancer: molecular mechanisms and clinical application. <i>Nature Reviews Cancer</i> , 2018, 18, 707-719.	28.4	324
45	Predictive values of two frailty screening tools in older patients with solid cancer: a comparison of SAOP2 and G8. <i>Oncotarget</i> , 2018, 9, 35056-35068.	1.8	19
46	Evaluation of prognostic indices in elderly hospitalized patients. <i>Geriatrics and Gerontology International</i> , 2017, 17, 1015-1021.	1.5	10
47	Algoplus® Scale in Older Patients with Dementia: A Reliable Real-World Pain Assessment Tool. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 519-527.	2.6	4
48	Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair. <i>Cancer Research</i> , 2017, 77, 3857-3869.	0.9	81
49	Personality traits and behavioral disturbances in dementia: A new risk factor?. <i>Geriatrics and Gerontology International</i> , 2017, 17, 851-852.	1.5	0
50	Pharmacological Sirt6 inhibition improves glucose tolerance in a type 2 diabetes mouse model. <i>FASEB Journal</i> , 2017, 31, 3138-3149.	0.5	62
51	Regulation and Function of Extracellular Nicotinamide Phosphoribosyltransferase/Visfatin. , 2017, 7, 603-621.		78
52	SIRT6 inhibitors with salicylate-like structure show immunosuppressive and chemosensitizing effects. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 5849-5858.	3.0	37
53	Nicotinic acid: A case for a vitamin that moonlights for cancer?. <i>Cell Cycle</i> , 2017, 16, 1635-1636.	2.6	6
54	Vitamin C, Aging and Alzheimer's Disease. <i>Nutrients</i> , 2017, 9, 670.	4.1	161

#	ARTICLE	IF	CITATIONS
55	Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model. <i>Oncotarget</i> , 2016, 7, 2968-2984.	1.8	57
56	Do Cancer Drugs Counteract Neurodegeneration? Repurposing for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 1295-1306.	2.6	32
57	Synthesis and biological characterization of 3-(imidazol-1-ylmethyl)piperidine sulfonamides as aromatase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 3192-3194.	2.2	30
58	Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. <i>Blood</i> , 2016, 127, 1138-1150.	1.4	89
59	Update on cardiotoxicity of anti-cancer treatments. <i>European Journal of Clinical Investigation</i> , 2016, 46, 264-284.	3.4	65
60	Systems medicine in colorectal cancer: from a mathematical model toward a new type of clinical trial. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2016, 8, 314-336.	6.6	11
61	Squalene epoxidase is a bona fide oncogene by amplification with clinical relevance in breast cancer. <i>Scientific Reports</i> , 2016, 6, 19435.	3.3	102
62	Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status. <i>Clinical Cancer Research</i> , 2016, 22, 6099-6109.	7.0	19
63	Systems Medicine in Oncology: Signaling Network Modeling and New-Generation Decision-Support Systems. <i>Methods in Molecular Biology</i> , 2016, 1386, 181-219.	0.9	12
64	Sirt6 regulates dendritic cell differentiation, maturation, and function. <i>Aging</i> , 2016, 8, 34-47.	3.1	28
65	The GSK3 β inhibitor BIS I reverts YAP-dependent EMT signature in PDAC cell lines by decreasing SMADs expression level. <i>Oncotarget</i> , 2016, 7, 26551-26566.	1.8	18
66	Transcription Factors Synergistically Activated at the Crossing of the Restriction Point between G1 and S Cell Cycle Phases. Pathologic Gate Opening during Multi-Hit Malignant Transformation. <i>Nuclear Receptor Research</i> , 2016, 3, .	2.5	0
67	EIF2A-dependent translational arrest protects leukemia cells from the energetic stress induced by NAMPT inhibition. <i>BMC Cancer</i> , 2015, 15, 855.	2.6	13
68	Amnestic Mild Cognitive Impairment and Conversion to Alzheimer's Disease: Insulin Resistance and Glycoxidation as Early Biomarker Clusters. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 89-95.	2.6	14
69	NAD ⁺ Levels Control T Cell Calcium Signaling and Activation. <i>Messenger (Los Angeles)</i> 10.784314. <small>0.3</small>	0.3	0
70	APO866 Increases Antitumor Activity of Cyclosporin-A by Inducing Mitochondrial and Endoplasmic Reticulum Stress in Leukemia Cells. <i>Clinical Cancer Research</i> , 2015, 21, 3934-3945.	7.0	31
71	Selectivity hot-spots of sirtuin catalytic cores. <i>Molecular BioSystems</i> , 2015, 11, 2263-2272.	2.9	24
72	Quinazolinone SIRT6 inhibitors sensitize cancer cells to chemotherapeutics. <i>European Journal of Medicinal Chemistry</i> , 2015, 102, 530-539.	5.5	78

#	ARTICLE	IF	CITATIONS
73	Treatment with KLEPTOSEÂ® CRYSMEB reduces mouse atherogenesis by impacting on lipid profile and Th1 lymphocyte response. <i>Vascular Pharmacology</i> , 2015, 72, 197-208.	2.1	14
74	Diminazene enhances stability of atherosclerotic plaques in ApoE-deficient mice. <i>Vascular Pharmacology</i> , 2015, 74, 103-113.	2.1	20
75	Fasting plus tyrosine kinase inhibitors in cancer. <i>Aging</i> , 2015, 7, 1026-1027.	3.1	6
76	Advances in dynamic modeling of colorectal cancer signaling-network regions, a path toward targeted therapies. <i>Oncotarget</i> , 2015, 6, 5041-5058.	1.8	24
77	Fasting potentiates the anticancer activity of tyrosine kinase inhibitors by strengthening MAPK signaling inhibition. <i>Oncotarget</i> , 2015, 6, 11820-11832.	1.8	67
78	Nicotinamide phosphoribosyltransferase inhibition reduces intraplaque CXCL1 production and associated neutrophil infiltration in atherosclerotic mice. <i>Thrombosis and Haemostasis</i> , 2014, 112, 308-322.	3.4	44
79	Statin Treatment Is Associated with Reduction in Serum Levels of Receptor Activator of NF- κ B Ligand and Neutrophil Activation in Patients with Severe Carotid Stenosis. <i>Mediators of Inflammation</i> , 2014, 2014, 1-11.	3.0	26
80	Nicotinamide Phosphoribosyltransferase Promotes Epithelial-to-Mesenchymal Transition as a Soluble Factor Independent of Its Enzymatic Activity. <i>Journal of Biological Chemistry</i> , 2014, 289, 34189-34204.	3.4	64
81	A critical role of autophagy in antileukemia/lymphoma effects of APO866, an inhibitor of NAD biosynthesis. <i>Autophagy</i> , 2014, 10, 603-617.	9.1	28
82	TLR activation of tumor-associated macrophages from ovarian cancer patients triggers cytolytic activity of NK cells. <i>European Journal of Immunology</i> , 2014, 44, 1814-1822.	2.9	91
83	Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal cytogenetics. <i>Leukemia Research</i> , 2014, 38, 649-659.	0.8	38
84	Discovery of Novel and Selective SIRT6 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 4796-4804.	6.4	94
85	Treatment with Angiotensin-(1-7) reduces inflammation in carotid atherosclerotic plaques. <i>Thrombosis and Haemostasis</i> , 2014, 111, 736-747.	3.4	47
86	Potential of crizotinib activity by fasting cycles in an ALK+ lung cancer model. <i>Journal of Clinical Oncology</i> , 2014, 32, e13511-e13511.	1.6	2
87	Synthesis of Pyrrolidine 3,4-Diol Derivatives with Anticancer Activity on Pancreatic Tumor Cells. <i>Heterocycles</i> , 2014, 88, 1445.	0.7	3
88	Synthesis and cancer growth inhibitory activities of 2-fatty-alkylated pyrrolidine-3,4-diol derivatives. <i>Arxiv</i> , 2014, 2014, 197-214.	0.5	11
89	The effect of preoperative chemoradiotherapy on lymph nodes harvested in TME for rectal cancer. <i>World Journal of Surgical Oncology</i> , 2013, 11, 292.	1.9	18
90	Inhibition of Nicotinamide Phosphoribosyltransferase Reduces Neutrophil-Mediated Injury in Myocardial Infarction. <i>Antioxidants and Redox Signaling</i> , 2013, 18, 630-641.	5.4	95

#	ARTICLE	IF	CITATIONS
91	Intracellular NAD ⁺ depletion induces autophagic death in multiple myeloma cells. <i>Autophagy</i> , 2013, 9, 410-412.	9.1	31
92	Tracking molecular relapse of chronic myeloid leukemia by measuring Hedgehog signaling status. <i>Leukemia and Lymphoma</i> , 2013, 54, 342-352.	1.3	8
93	CD73 Protein as a Source of Extracellular Precursors for Sustained NAD ⁺ Biosynthesis in FK866-treated Tumor Cells. <i>Journal of Biological Chemistry</i> , 2013, 288, 25938-25949.	3.4	129
94	Autophagy in blood cancers: biological role and therapeutic implications. <i>Haematologica</i> , 2013, 98, 1335-1343.	3.5	54
95	Glucagon-Like Peptide-1 Triggers Protective Pathways in Pancreatic Beta-Cells Exposed to Glycated Serum. <i>Mediators of Inflammation</i> , 2013, 2013, 1-10.	3.0	11
96	An Emerging Role of Glucagon-Like Peptide-1 in Preventing Advanced-Glycation-End-Product-Mediated Damages in Diabetes. <i>Mediators of Inflammation</i> , 2013, 2013, 1-9.	3.0	20
97	Role of Mitogen-Activated Protein Kinase Pathways in Multifactorial Adverse Cardiac Remodeling Associated with Metabolic Syndrome. <i>Mediators of Inflammation</i> , 2013, 2013, 1-11.	3.0	24
98	Intracellular NAD ⁺ depletion enhances bortezomib-induced anti-myeloma activity. <i>Blood</i> , 2013, 122, 1243-1255.	1.4	74
99	Pathophysiological role of neutrophils in acute myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2013, 110, 501-514.	3.4	138
100	Rejuvenating Sirtuins: The Rise of a New Family of Cancer Drug Targets. <i>Current Pharmaceutical Design</i> , 2013, 19, 614-623.	1.9	49
101	Evidence on the pathogenic role of auto-antibodies in acute cardiovascular diseases. <i>Thrombosis and Haemostasis</i> , 2013, 109, 854-868.	3.4	49
102	Editorial (Thematic Issue: Chronic Myeloid Leukemia: Reaching For the Cure). <i>Current Cancer Drug Targets</i> , 2013, 13, 709-710.	1.6	0
103	Editorial (Thematic Issue: NAD ⁺ Biosynthesis and Signaling as an Emerging Area in) <i>Trends in Biochemical Sciences</i> , 2013, 38, 1-5.	1.0784314	14
104	New Insights Into Biology of Chronic Myeloid Leukemia: Implications in Therapy. <i>Current Cancer Drug Targets</i> , 2013, 13, 711-723.	1.6	10
105	The vulnerable coronary plaque: update on imaging technologies. <i>Thrombosis and Haemostasis</i> , 2013, 110, 706-722.	3.4	30
106	Treatment with the CC chemokine-binding protein Evasin-4 improves post-infarction myocardial injury and survival in mice. <i>Thrombosis and Haemostasis</i> , 2013, 110, 807-825.	3.4	46
107	Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Therapeutics: Rationales, Controversies, Clinical Experience. <i>Current Drug Targets</i> , 2013, 14, 637-643.	2.1	48
108	Evaluating Treatment Response of Chronic Myeloid Leukemia: Emerging Science and Technology. <i>Current Cancer Drug Targets</i> , 2013, 13, 779-790.	1.6	15

#	ARTICLE	IF	CITATIONS
109	Nicotinamide Phosphoribosyltransferase as a Target in Inflammation- Related Disorders. <i>Current Topics in Medicinal Chemistry</i> , 2013, 13, 2930-2938.	2.1	27
110	NAD ⁺ Levels Control Ca ²⁺ Store Replenishment and Mitogen-induced Increase of Cytosolic Ca ²⁺ by Cyclic ADP-ribose-dependent TRPM2 Channel Gating in Human T Lymphocytes. <i>Journal of Biological Chemistry</i> , 2012, 287, 21067-21081.	3.4	50
111	Targeting NAD ⁺ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. <i>Blood</i> , 2012, 120, 3519-3529.	1.4	133
112	The NAD ⁺ -dependent Histone Deacetylase SIRT6 Promotes Cytokine Production and Migration in Pancreatic Cancer Cells by Regulating Ca ²⁺ Responses. <i>Journal of Biological Chemistry</i> , 2012, 287, 40924-40937.	3.4	151
113	The plant hormone abscisic acid increases in human plasma after hyperglycemia and stimulates glucose consumption by adipocytes and myoblasts. <i>FASEB Journal</i> , 2012, 26, 1251-1260.	0.5	81
114	Proteasome Inhibitors as Immunosuppressants: Biological Rationale and Clinical Experience. <i>Seminars in Hematology</i> , 2012, 49, 270-276.	3.4	37
115	Rejuvenating Sirtuins: The Rise of a New Family of Cancer Drug Targets. <i>Current Pharmaceutical Design</i> , 2012, 19, 614-623.	1.9	1
116	Synergistic Interactions between HDAC and Sirtuin Inhibitors in Human Leukemia Cells. <i>PLoS ONE</i> , 2011, 6, e22739.	2.5	68
117	Anti-cancer activity of 5-O-alkyl 1,4-imino-1,4-dideoxyribitols. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 7720-7727.	3.0	13
118	Dynamic Simulations of Pathways Downstream of ERBB-Family: Exploration of Parameter Space and Effects of Its Variation on Network Behavior. <i>Lecture Notes in Computer Science</i> , 2011, , 229-241.	1.3	0
119	Targeting NAD ⁺ Salvage Pathway Induces Autophagy in Multiple Myeloma Cells. <i>Blood</i> , 2011, 118, 2920-2920.	1.4	0
120	Ras-Induced Resistance to Lapatinib is Overcome by MEK Inhibition. <i>Current Cancer Drug Targets</i> , 2010, 10, 168-175.	1.6	26
121	Novel 2-[(benzylamino)methyl]pyrrolidine-3,4-diol derivatives as α -mannosidase inhibitors and with antitumor activities against hematological and solid malignancies. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 3320-3334.	3.0	24
122	Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells. <i>Experimental Hematology</i> , 2010, 38, 979-988.	0.4	48
123	A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib. <i>Leukemia Research</i> , 2010, 34, e240-e242.	0.8	15
124	Synthesis of new oxathiazinane dioxides and their in vitro cancer cell growth inhibitory activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 5353-5356.	2.2	4
125	Grb7 Upregulation Is a Molecular Adaptation to HER2 Signaling Inhibition Due to Removal of Akt-Mediated Gene Repression. <i>PLoS ONE</i> , 2010, 5, e9024.	2.5	35
126	Monoclonal Antibodies for Non-Hodgkin's Lymphoma: State of the Art and Perspectives. <i>Clinical and Developmental Immunology</i> , 2010, 2010, 1-14.	3.3	20

#	ARTICLE	IF	CITATIONS
127	Hedgehog Signaling Is Useful as a Novel Molecular Marker for Predicting Relapse and Resistance During Chronic Myeloid Leukemia Treatment.. Blood, 2010, 116, 1215-1215.	1.4	1
128	Catastrophic NAD+ Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAE. PLoS ONE, 2009, 4, e7897.	2.5	143
129	APO866 activity in hematologic malignancies: a preclinical in vitro study. Blood, 2009, 113, 6035-6037.	1.4	24
130	Potent Synergistic Activity of the NAD+ Synthesis Inhibitor APO866 and of the Apoptosis Inducer TRAIL in in Vitro and Ex Vivo Cellular Models of Non Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia.. Blood, 2009, 114, 2733-2733.	1.4	28
131	Deacetylase Inhibitor Cocktails Provide Striking Synergistic Interactions in Human Leukemia Cells.. Blood, 2009, 114, 4404-4404.	1.4	0
132	Catastrophic NAD+ Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAE.. Blood, 2009, 114, 4732-4732.	1.4	0
133	Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas. Annals of Hematology, 2008, 87, 49-55.	1.8	25
134	The use of dendritic cells in cancer immunotherapy. Critical Reviews in Oncology/Hematology, 2008, 65, 191-199.	4.4	84
135	Immunotherapy with dendritic cells for cancer. Advanced Drug Delivery Reviews, 2008, 60, 173-183.	13.7	54
136	Crosspresentation: a matter of pH. Blood, 2008, 112, 4368-4369.	1.4	3
137	Histone Deacetylase Inhibitors Affect Dendritic Cell Differentiation and Immunogenicity. Clinical Cancer Research, 2007, 13, 3933-3941.	7.0	144
138	Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells. European Journal of Immunology, 2006, 36, 681-689.	2.9	71
139	Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation. Blood, 2006, 108, 551-558.	1.4	128
140	The Proteasome and Its Inhibitors in Immune Regulation and Immune Disorders. Critical Reviews in Immunology, 2006, 26, 487-498.	0.5	23
141	Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis. Blood, 2005, 105, 3255-3262.	1.4	114
142	Cooperative Cytotoxicity of Proteasome Inhibitors and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in Chemoresistant Bcl-2-Overexpressing Cells. Clinical Cancer Research, 2005, 11, 4259-4265.	7.0	57
143	RNAI AS AN EXPERIMENTAL AND THERAPEUTIC TOOL TO STUDY AND REGULATE PHYSIOLOGICAL AND DISEASE PROCESSES. Annual Review of Physiology, 2005, 67, 147-173.	13.1	96
144	Proteasome Inhibitors Affect the Function of Human Dendritic Cells and Induce Caspase-Mediated Apoptosis.. Blood, 2005, 106, 2229-2229.	1.4	0

#	ARTICLE	IF	CITATIONS
145	Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Cooperates with Anticancer Drugs to Overcome Chemoresistance in Antiapoptotic Bcl-2 Family Members Expressing Jurkat Cells. <i>Clinical Cancer Research</i> , 2004, 10, 1463-1470.	7.0	36
146	Cellular Immunotherapy with Dendritic Cells in Cancer: Current Status. <i>Stem Cells</i> , 2004, 22, 501-513.	3.2	44
147	RNA interference for the identification of disease-associated genes. <i>Current Opinion in Molecular Therapeutics</i> , 2004, 6, 136-40.	2.8	4
148	Dendritic cells transfected with tumor RNA for the induction of antitumor CTL in colorectal cancer. <i>Cancer Gene Therapy</i> , 2003, 10, 209-214.	4.6	42
149	Transfection of Dendritic Cells with RNA Induces CD4- and CD8-Mediated T Cell Immunity Against Breast Carcinomas and Reveals the Immunodominance of Presented T Cell Epitopes. <i>Journal of Immunology</i> , 2003, 170, 5892-5896.	0.8	85
150	Cyclopentenone Prostaglandins Induce Lymphocyte Apoptosis by Activating the Mitochondrial Apoptosis Pathway Independent of External Death Receptor Signaling. <i>Journal of Immunology</i> , 2003, 171, 5148-5156.	0.8	51
151	Role of Peroxisome Proliferator-Activated Receptor γ and Its Ligands in the Control of Immune Responses. <i>Critical Reviews in Immunology</i> , 2003, 23, 1-13.	0.5	58
152	Dendritic Cell Immunogenicity Is Regulated by Peroxisome Proliferator-Activated Receptor δ . <i>Journal of Immunology</i> , 2002, 169, 1228-1235.	0.8	190
153	Cyclopentenone prostaglandins induce caspase activation and apoptosis in dendritic cells by a PPAR- δ -independent mechanism. <i>Experimental Hematology</i> , 2002, 30, 1020-1028.	0.4	40
154	New Perspectives in Dendritic Cell-Based Cancer Immunotherapy. <i>BioDrugs</i> , 2001, 15, 667-679.	4.6	7
155	Reverse-transcriptase polymerase chain reaction of the maspin gene in the detection of bone marrow breast carcinoma cell contamination. <i>Cancer</i> , 2001, 92, 2030-2035.	4.1	21
156	Safety and tolerability of intravenous ferric carboxymaltose in the oldest old patients: a prospective cohort study in a University Italian Geriatrics Department. <i>Journal of Gerontology and Geriatrics</i> , 0, , 1-4.	0.5	1